FDA
-
-
-
-
-
-
-
Tempus receives FDA approval for tumor-only xT CDx genomic test
-
-
-
-
-
-
-
FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.
-
-
-
-
-
-
-
Ambry Genetics enhances breast cancer risk assessment tool with breast density
-
-
-
-
-
-
-
Tempus receives FDA clearance for updated cardiac imaging device
-
-
-
-
-
-
-
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
-
-
-
-
-
-
-
Artificial Intelligence (AI) Influence on Healthcare Market Expected to Generate Revenues of $610 Billion By 2034
-
-
-
-
-
-
-
Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

